Highlight of 2023: Virtues and vices of CD4 CAR T cells

Shivali Savita Chinni; Megan F Taylor; Jessica G Borger; Kylie M Quinn

doi:10.1111/imcb.12764

Highlight of 2023: Virtues and vices of CD4 CAR T cells

Immunol Cell Biol. 2024 Jul;102(6):432-436. doi: 10.1111/imcb.12764. Epub 2024 Apr 24.

Authors

Shivali Savita Chinni¹, Megan F Taylor^{2

3}, Jessica G Borger^{2

3}, Kylie M Quinn^{1

4}

Affiliations

¹ School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, Australia.
² The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
³ Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia.
⁴ Department of Biochemistry, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.

PMID: 38659345
DOI: 10.1111/imcb.12764

Abstract

This article for the Highlights of 2023 Series explores recent work that suggests that targeting CD4 CAR T cells may be critical for both of these challenges.

Keywords: CAR T cell therapy; CD4; IFN‐γ; cytokine release syndrome.

MeSH terms

Animals
CD4-Positive T-Lymphocytes* / immunology
Humans
Immunotherapy, Adoptive* / methods
Receptors, Antigen, T-Cell / immunology
Receptors, Antigen, T-Cell / metabolism
Receptors, Chimeric Antigen* / genetics
Receptors, Chimeric Antigen* / immunology
Receptors, Chimeric Antigen* / metabolism

Substances

Receptors, Chimeric Antigen
Receptors, Antigen, T-Cell

Abstract

MeSH terms

Substances

Grants and funding